DUBLIN–(BUSINESS WIRE)–The “Biopharmaceutical Fermentation Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F” report has been added to ResearchAndMarkets.com’s offering.
Global Biopharmaceutical Fermentation Market has valued at USD 24.82 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.15% through 2028
The Biopharmaceutical Fermentation Market is characterized by a growing pipeline of biopharmaceuticals, the expanding biosimilars market, regulatory complexities, the need for consistent product quality, and transformative trends like continuous fermentation and single-use bioreactors. The dominance of downstream products and the pivotal role of biopharmaceutical industries contribute to the market’s dynamics, with North America at the forefront of growth.
Factors such as the increasing demand for biotech-based drugs and rising research and development activities to produce novel biological drugs are boosting market growth. For instance, according to the 2021 annual report of AbbVie, Humira is one of the top-selling biotechnology drugs in the world which accounted for net revenues of USD 20.7 billion and approximately 37% of AbbVie’s total net revenues in 2021.
Globally, Humira sales increased by 4% in 2021 compared with the previous year. Similarly, as per the 2021 annual report of Merck & Co, the sales of Keytruda, one of the major biotech-based drugs of the company, grew by 20% to USD 17.2 Billion, compared to USD 14.9 Billion in the year 2020. Thus, the increasing sales of biotech-based drugs in the market indicates the increasing demand for these drugs in the market which in turn is anticipated to fuel the market growth over the forecast period.
Furthermore, the rising company focus on developing novel biological drugs is also expected to fuel the demand for fermentation services and products which is anticipated to propel the market growth. For instance, in November 2022, Eikonoklastes Therapeutics, a preclinical biotech company, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization entered a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS). Also, in August 2022, Sanofi and Innovent Biologics entered a strategic collaboration to accelerate the development of two biologic oncology medicines (tusamitamab ravtansine, SAR444245) and expand their presence in China.
Therefore, owing to the factors, such as the rising company activities and increasing demand for biotech-based drugs, the studied market is anticipated to grow over the forecast period. However, the high cost of biopharmaceutical fermentation and installation is likely to impede the growth of the biopharmaceutical fermentation market over the forecast period.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 178 |
| Forecast Period | 2023 – 2028 |
| Estimated Market Value (USD) in 2023 | $24.82 Billion |
| Forecasted Market Value (USD) by 2028 | $39.46 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
Key Market Drivers
Market Drivers:
- Growing Pipeline of Biopharmaceuticals: The expansion of the therapeutic landscape, the emergence of biosimilars, and investments in R&D drive the growth of the biopharmaceutical pipeline.
- Expanding Biosimilars Market: Biosimilars offer cost-effective alternatives to approved biopharmaceuticals, contributing to their growing demand and manufacturing.
Key Challenges:
- Regulatory Complexities: Meeting stringent regulatory requirements, including validation and compliance with evolving global standards, poses challenges for biopharmaceutical fermentation.
- Ensuring Consistent Product Quality: Maintaining product consistency in biopharmaceutical manufacturing is challenging due to inherent variability and the need for rigorous control.
Key Trends:
- Continuous Fermentation: Continuous fermentation processes enhance efficiency, reduce downtime, and offer cost savings, making them a transformative trend in biopharmaceutical manufacturing.
- Single-Use Bioreactors: Single-use bioreactors replace traditional systems, offering flexibility, reduced contamination risk, and cost-efficiency.
Segmental Insights:
- Product Type: Downstream products are dominant due to their critical role in ensuring product quality, safety, and compliance in biopharmaceutical production.
- End User: Biopharmaceutical industries are prominent players, driving innovation, global expansion, and compliance with regulatory standards.
Regional Insights:
- North America is expected to witness significant growth, driven by rising demand for biotech-based drugs, research and development activities, and a high burden of diseases like diabetes and cancer.
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Biopharmaceutical Fermentation Market.
- Agilent Technologies Inc
- Thermo Fisher Scientific Inc.
- Lonza Group AG
- Sartorius Stedim Biotech GmbH
- Eppendorf Inc
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Nova Biomedical Corporation
- Merck KGaA
- Becton, Dickinson and Company
Report Scope:
Biopharmaceutical Fermentation Market, By Product Type:
- Upstream Products
- Downstream Products
Biopharmaceutical Fermentation Market, By Application:
- Antibiotics
- Recombinant Proteins
- Others
Biopharmaceutical Fermentation Market, By End User:
- Biopharmaceutical Industries
- Contract Research Organization
- Academic Research Institutes
- Others
Biopharmaceutical Fermentation Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
For more information about this report visit https://www.researchandmarkets.com/r/tyis8m
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900